Depends on the strength of the data. Assume that a P3 will be needed, however if the data shows a very good or strong positive effect then The Boss will broach the subject of getting leronlimab out to the patients more quickly with the FDA. Leronlimab has shown it is a safe drug already....so like usual...it all depends!